Windlas Biotech Limited has scheduled a Board of Directors meeting for April 17, 2026, to consider and approve a share buyback proposal for its fully paid-up equity shares. The buyback will be conducted in accordance with the Companies Act, 2013, and SEBI Buy-Back Regulations, 2018. The company has also informed that trading window restrictions remain in effect from April 1, 2026, for designated persons until 48 hours after the annual financial results for the year ended March 31, 2026, become publicly available.

Windlas Biotech Limited Board Meeting Scheduled for April 17, 2026 to Consider Share Buyback Proposal

Windlas Biotech Limited has announced a Board of Directors meeting scheduled for April 17, 2026, to consider a significant corporate action involving the buyback of its equity shares. The pharmaceutical company has informed stock exchanges about this development through a formal communication dated April 14, 2026.

Board Meeting Details

The upcoming board meeting will focus on a comprehensive review and approval of the share buyback proposal. The company has outlined the key aspects of this corporate action in its regulatory filing.

Parameter: Details Meeting Date: April 17, 2026 Purpose: Consider and approve share buyback proposal Share Type: Fully paid-up equity shares Regulatory Framework: Companies Act, 2013 and SEBI Buy-Back Regulations, 2018

Regulatory Compliance Framework

The proposed buyback will be conducted in strict adherence to multiple regulatory requirements. The company has emphasized compliance with the Companies Act, 2013, including rules framed thereunder, and the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended. All matters necessary and incidental to the buyback process will be addressed during the board deliberations.

Trading Window Restrictions

Windlas Biotech has implemented trading restrictions for designated persons as part of its insider trading prevention measures. The company has provided specific details regarding the current trading window closure.

Restriction Details: Information Trading Window Status: Closed Effective From: April 1, 2026 Applicable To: All designated persons and immediate relatives Closure Duration: Until 48 hours after annual results become public Results Period: Year ended March 31, 2026

These restrictions are implemented pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Regulating, Monitoring & Reporting of Trading.

Corporate Communication

The announcement was made through official communications to both major stock exchanges where the company's shares are listed. Windlas Biotech has requested the exchanges to take this information on record, ensuring transparency and regulatory compliance in its corporate actions.

Windlas biotech Limited has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE and NSE on April 6, 2026.

Quarterly Compliance Certificate Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The document pertains to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Parameter: Details Quarter Period: March 31, 2026 Certificate Date: April 03, 2026 Filing Date: April 06, 2026 Registrar: MUFG Intime India Private Limited

Key Confirmation

MUFG Intime India Private Limited confirmed that during the quarter ended March 31, 2026, no demat requests were received for processing. The registrar specifically noted that Windlas Biotech Limited does not have any physical shares outstanding, indicating that all shares are already in dematerialized form.

Regulatory Compliance

The submission was made to the compliance departments of both major Indian stock exchanges. Company Secretary and Compliance Officer Ananta Narayan Panda signed the filing letter, ensuring adherence to regulatory requirements. This quarterly certificate filing is a standard compliance requirement for listed companies under SEBI regulations.

Company Information

Windlas Biotech Limited operates from its registered office in Dehradun, Uttarakhand, with its corporate office located in Gurgaon, Haryana. The company maintains its listing on both BSE and NSE, trading under the symbols 543329 and WINDLAS respectively.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.